Intelligence · Clinical Development
Pipeline search results
Programs matching “Astra” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 467 pipeline programs matching "Astra" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
IMFINZI 50 mg/mL concentrate for solution for infusion.
AstraZeneca AB
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIBIV)
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
AstraZeneca AB
Patients With Muscle-Invasive Bladder Cancer
1 trial -
IRST185.04
Istituto Gentili S.r.l.
metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)
1 trial -
ISIS EIF4E Rx
IONIS PHARMACEUTICALS INC
Castrate-Resistant Prostate Cancer
1 trial -
Irofulven
Allarity Therapeutics
Metastatic Castration-Resistant Prostate Cancer Patients
1 trial -
Lutetium (177Lu) rhPSMA-10.1 injection
Blue Earth Diagnostics Ireland Ltd
Metastatic castration-resistant prostate cancer (mCRPC)
1 trial -
MEDI4736
AstraZeneca
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
1 trial -
MK-2400-01A
Merck Sharp and Dohme
Metastatic castrate resistant prostate cancer - mCRPC
1 trial -
MK-3475-365
Merck Sharp and Dohme
Metastatic Castration-Resistant Prostate Cancer
1 trial -
MK-5684-01A
Merck Sharp and Dohme
Metastatic castration resistant prostate cancer (mCRPC)
1 trial -
NRX 194204
IO Biotech
Castration Resistant Prostate Cancer
1 trial -
Olaparib Continuous (28-Day cycle) 300 mg BD.
AstraZeneca
Metastatic Triple Negative Breast Cancer
1 trial -
OlympiaN
AstraZeneca AB
BRCA Mutations and Early Stage HER2-Negative Breast Cancer
1 trial -
Onvansertib
Cardiff Oncology
Metastatic Castration-Resistant Prostate Cancer
1 trial -
Osimertinib + Savolitinib
AstraZeneca
Non-Small Cell Lung Cancer
1 trial -
Osimertinib 80 mg/40 mg
AstraZeneca
Stage II-IIIB Non-small Cell Lung Carcinoma
1 trial -
PURSUIT
AstraZeneca AB
Dyslipidemia Dyslipidemias are alterations to the plasma lipid profile associated often with clinical condition. A common form of dyslipidemia is Hypercholesterolemia due to high level of LDL-cholesterol, which is a major risk factor for Cardiovascular Disease (CVD), such as Ischemic Heart Disease and Ischemic Stroke. CVD is a leading cause of global mortality and a contributor to disability.
1 trial -
Pembrolizumab
United Therapeutics Europe Ltd
Castration-resistant Prostate Cancer
1 trial -
Pembrolizumab 200 mg
Merck KGaA, Darmstadt, Germany
Metastatic Castration-Resistant Prostate Cancer
1 trial -
Placebo for AZD4144, AZD4144
AstraZeneca AB
Sepsis-associated acute kidney injury (AKI)
1 trial -
Placebo for AZD5148, AZD5148
AstraZeneca AB
Recurrence of Clostridioides difficile Infection
1 trial -
REGN15505
Regeneron UK Limited
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1 trial -
REGN4336
Regeneron UK Limited
Metastatic Castration-resistant Prostate Cancer
1 trial -
REGN5678
Regeneron UK Limited
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.